Practical guidance on the ISO 10993-1:2025 transition, biological evaluation best practices, and what notified bodies are looking for.
Tables 1 through 4 replaced Table A.1. Contact days replaced hours. Intermittent contact, bioaccumulation, and foreseeable misuse all change how you categorize your device. When the tables are not enough and what your documentation needs to show.
Read articleThese biological effects are not universally required but have specific triggers in the standard. The conditions that require evaluation, what the BER needs to document, and where qualified scientific judgment is essential.
Read articleISO 10993-1:2025 aligns biological evaluation with ISO 14971 risk management. The hazard-to-harm chain, where BERs commonly fall short, and concrete examples of what does and does not constitute a hazardous situation.
Read articleSolvent selection rationale, AET calculation methodology, polarity coverage, identified vs unidentified peaks, and how E&L data must connect to your toxicological risk assessment. Where documentation gaps most commonly appear.
Read articleMost deficiencies are documentation problems, not science problems. A structured pre-submission review catches weak justifications, missing cross-references, and scope gaps before the notified body does.
Read articleBoth markets require ISO 10993, but the review mechanics are different. Endpoint selection, equivalence frameworks, CMR substances, documentation lifecycle, and where deficiency findings diverge.
Read articleWeak justifications are the most common cause of avoidable deficiency findings. A practical framework for writing rationale that holds up under FDA and notified body scrutiny, with side-by-side weak vs. strong examples.
Read articleISO 10993-1:2025 requires evaluation at maximum validated reprocessing cycles. When T0 and T-end are sufficient, when intermediate timepoints are needed, and how to document the justification.
Read articleISO 10993-1:2025 requires explicit justification for every excluded biological effect. What reviewers expect, common errors, and how to document exclusions that hold up under scrutiny.
Read articleChemical characterization and TRA can replace animal testing for several biocompatibility endpoints. Here is what sufficient data looks like in practice, and where the approach reaches its limits.
Read articleThe most frequently cited deficiencies in biological evaluation documentation, based on published FDA guidance and documented notified body expectations. What to check before you submit.
Read articleExternal expert, internal team, or structured evaluation tool. Three approaches to pre-submission review, and when each makes sense for your documentation.
Read articleWhat notified body reviewers focus on, what preparation looks like in practice, and how to strengthen your package before submission.
Read articleBioEvalPro is a documentation quality tool, not a consultancy. Here's how it works alongside your regulatory team, toxicologists, and contracted experts to strengthen your 10993 package before submission.
Read articleAlready have ISO 10993 documentation from the 2018 standard? BioEvalPro identifies exactly what needs updating before your next notified body review. Here's how the transition checker works.
Read articleThe sixth edition of ISO 10993-1 was published in November 2025. Here’s what actually changed, what it means for your biological evaluation documentation, and where to focus your transition efforts.
Read articleA side-by-side comparison of the fifth and sixth editions, focusing on the changes that require documentation updates.
Read articleOne of the most significant new requirements in the 2025 standard. What qualifies as foreseeable misuse and how to address it in your BER.
Read articleBioEvalPro evaluates your ISO 10993 documentation for gaps, weak justifications, and regulatory alignment.